News
Axios on MSN12d
Vinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
Hosted on MSN13d
US FDA names agency critic Vinay Prasad as top vaccine official(Reuters) -The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA ...
In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...
MedPage Today on MSN12dOpinion
Vinay Prasad Speaks to CBER Staff: Which Prasad Showed Up?The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...
WEDNESDAY, May 7, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a ...
has chosen Dr. Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research. The division oversees vaccines and biologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback